Process development and optimization form the backbone of radiopharmaceutical manufacturing, transforming bench-scale radiochemistry into robust, reproducible, and scalable production workflows capable of meeting stringent cGMP standards. At Protheragen, our integrated development platform guides each radiopharmaceutical candidate from initial reaction screening through validated commercial processes, ensuring that critical quality attributes are preserved at every scale.
Process development for radiopharmaceuticals encompasses the systematic design, evaluation, and refinement of every manufacturing step required to produce a consistent, safe, and efficacious drug product. Unlike conventional pharmaceuticals, radiopharmaceuticals introduce unique constraints: radioisotopes decay continuously, meaning production timelines are compressed and shelf-life is often measured in hours rather than months. The manufacturing process must therefore balance radiochemical yield, specific activity, and purity against the relentless countdown of isotope half-life. This demands a highly integrated approach in which precursor synthesis, radiolabeling chemistry, purification, formulation, and quality control are not treated as isolated steps but as interdependent components of a single, time-critical workflow. Process optimization further refines these steps by identifying critical process parameters (CPPs), establishing design spaces through Quality by Design (QbD) principles, and applying Design of Experiments (DoE) to maximize robustness while minimizing variability.
Fig 1. Timeline highlighting key milestones in the evolution of radiopharmaceutical synthesis from manual processes to modern cassette-based automation and next-generation microfluidic and AI-assisted systems. (Ko, Nare, et al., 2025)
| Trend / Challenge | Key Technologies / Approaches | Application Focus |
|---|---|---|
| Automation and Closed-System Synthesis | Cassette-based synthesizers, robotic dispensing, remote handling in hot cells | All diagnostic and therapeutic isotopes |
| AI-Driven Process Optimization | Machine learning for real-time release testing, predictive maintenance, anomaly detection | Scale-up, quality control, supply chain forecasting |
| Modular and Flexible Facility Design | Prefabricated cleanroom modules, pivotable manufacturing zones, digital twin simulation | Multi-isotope, multi-product facilities |
| Continuous and Hybrid Manufacturing | Microfluidic radiolabeling, continuous purification, integrated batch-continuous workflows | Short-half-life isotopes (Ga-68, F-18, Cu-64) |
| Supply Chain and Isotope Security | Dual-source qualification, on-site cyclotron integration, strategic inventory management | Ac-225, Pb-212, Lu-177, Ge-68/Ga-68 generators |
| Sterility and Contamination Control | Grade A isolators, single-use technologies, segregated production rooms, one-room-one-product concepts | All sterile injectable radiopharmaceuticals |
| Workforce and Expertise Development | Cross-functional training (radiochemistry, QA, radiation safety, logistics) | Academic radiopharmacies, CDMOs, commercial manufacturers |
Protheragen offers comprehensive process development and optimization services that bridge the gap between exploratory radiochemistry and cGMP-compliant manufacturing. Our multidisciplinary team applies Quality by Design principles, phase-appropriate validation strategies, and risk-based process controls to every program—whether it involves optimizing a novel alpha-emitter conjugation, scaling a beta-therapeutic from millicurie to multicurie batches, or transferring a diagnostic tracer process into a fully automated, cassette-based synthesizer.
We design and screen radiolabeling reaction conditions—including pH, temperature, buffer composition, and stoichiometry—to identify robust protocols that maximize radiochemical yield and specific activity while preserving vector integrity for peptides, antibodies, and small-molecule ligands.
Systematic evaluation of DOTA, NOTA, NODAGA, DFO, and proprietary macrocyclic chelators to match the radiometal's coordination chemistry with the targeting vector's structural constraints, ensuring stable conjugation under physiological and manufacturing conditions.
Development and optimization of solid-phase extraction, size-exclusion chromatography, and preparative HPLC protocols to achieve >95% radiochemical purity, with scalability assessed from analytical to preparative and GMP production scales.
Formulation development for liquid, lyophilized, and kit-based presentations, including excipient screening, pH optimization, and accelerated stability studies to define shelf-life, storage conditions, and in-use stability for both clinical trial and commercial supply.
Development and phase-appropriate qualification of orthogonal analytical methods—radio-HPLC, radio-TLC, LC-MS, radionuclidic purity assays, and endotoxin testing—to support in-process control, release testing, and stability monitoring.
Structured scale-up from laboratory to pilot and cGMP manufacturing, including equipment qualification, batch record authoring, and technology transfer packages that ensure process equivalence, reproducibility, and regulatory readiness across facilities.
Each process development campaign at Protheragen follows a structured, milestone-driven workflow that integrates radiochemistry, analytical science, and regulatory strategy from the outset. This approach ensures that process knowledge accumulates systematically, risks are identified and mitigated early, and every stage builds toward a cGMP-ready manufacturing package.
Whether you are refining a radiolabeling protocol for a novel alpha-emitter therapeutic, scaling a diagnostic tracer from bench to cGMP, or seeking a trusted partner to manage your entire CMC strategy, Protheragen is equipped to guide your program at every stage. Please contact us to discuss your process development requirements, or reach out to our technical team to schedule a feasibility review. We look forward to collaborating with you to transform your radiopharmaceutical concept into a robust, regulator-ready manufacturing process.
Reference